G42-HEALTHCARE
The first WHO enlisted global clinical Phase III trial of Sinopharm CNBG’s inactivated vaccine to combat COVID-19 has started in Abu Dhabi, inspired by the UAE Leadership’s commitment to overcome the pandemic through a global collaborative effort.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200717005085/en/
H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase III inactivated vaccine for COVID-19 that is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer.
The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application. They are being operated by Abu Dhabi Health Services (SEHA) who are providing clinical facilities.
UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate and G42 Healthcare and SEHA are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.
Chairperson of the UAE National COVID-19 Clinical Management Committee Dr. Nawal Ahmed Alkaabi said: “Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. We are proud to facilitate the testing process that if successful leads to the manufacture of a vaccine.”
It follows successful phase I and II trials by Sinopharm in China, resulting in 100% of volunteers generating antibodies.
G42 Healthcare CEO Ashish Koshy said: “We are enormously proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials.”
Jingjin Zhu, President, Biological products, Sinopharm CNBG added: “The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background. We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide.”
*Source : AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200717005085/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duetti Secures $200 Million to Scale Independent Music Catalog Acquisitions and Enhance Platform Capabilities21.1.2026 14:01:00 CET | Press release
Funding Led by a $50 Million Series C Equity Investment from The Raine Group Duetti Inc. (“Duetti” or the “Company”), the music-tech and financial services company that empowers independent music creators to unlock the value of their music catalogs, today announces it has secured $200 million in new funding to accelerate music catalog acquisitions and expand its technology and services globally. The financing is led by a $50 million Series C equity investment by Raine Partners, the flagship growth equity fund of The Raine Group, alongside a second $125 million private securitization and a $25 million increase of an existing credit facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121033285/en/ In over three years, Duetti has raised over $635 million, including over $100 million in equity, to support the global independent music community. To date, the Company has partnered with more than 1,100 artists, songwriters,
Board Collaborates with Microsoft to Bring Agentic AI Into the Core of Enterprise Planning21.1.2026 14:00:00 CET | Press release
Domain-Specific, Enterprise-Ready AI Agents Support Continuous Planning Across Finance, Supply Chain and Merchandising Board, one of the leading Enterprise Planning Platforms, today announced the launch of Board Agents built on Microsoft Foundry. Board Agents deliver an intelligent suite of domain-specific, enterprise-ready AI agents that support real-world planning decisions across finance, supply chain, and merchandising. This marks the first Board enterprise planning capability developed with Microsoft Foundry, using Microsoft Azure’s agentic AI tools and services to accelerate secure, cloud-native AI innovation. The initial release includes FP&A and Controller Agents for the Office of Finance, with Merchandiser and Supply Chain Agents to follow. Board Agents are built natively into the Board Enterprise Planning Platform, providing a secure, governed foundation for applying agentic AI to high-impact planning use cases. “As interest in AI accelerates, many customers are looking for c
Copeland Advances AI and Digital Strategy with Acquisition of Bueno Analytics21.1.2026 13:00:00 CET | Press release
Acquisition integrates advanced SaaS capabilities to deliver smarter, data‑driven HVAC and cold chain solutions Copeland, a global provider of compression technologies and controls solutions, announced today that it has entered into an agreement to acquire Bueno Analytics (“Bueno”), an Australia-based company specializing in SaaS solutions that leverage embedded AI and machine learning to deliver building analytics, energy management and operational efficiency across commercial buildings and the cold chain. Bueno’s platform is deployed across several thousand customer sites worldwide, providing broad connectivity, full portfolio visibility and critical operational insights. Buildings account for an estimated 40% of global carbon emissions, with commercial buildings and the cold chain representing a significant share of that impact. The integration of Bueno’s platform with Copeland’s deep domain expertise will deliver a powerful suite of capabilities, including predictive maintenance, e
NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine21.1.2026 13:00:00 CET | Press release
Today, NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical teams treating extremity-injured personnel (including those who have undergone tourniquet application) to assess and monitor tissue perfusion and oxygenation in real time. Why this matters In the battlefield context, timely recognition of compromised tissue perfusion (particularly in limbs subject to tourniquet use, major soft‐tissue injury or ischemia-reperfusion risk) can make the difference between viable salvage of the limb, avoidance of secondary complications, and optimal patient outcomes. The donated NIRSense kits, which will be administered by the Ukraine MoD under an approved protocol, may provi
Allshares Acquires U.S. Market Leader Stock & Option Solutions, Solidifying Its Position as a Global Leader in Equity Ownership Management21.1.2026 12:00:00 CET | Press release
Allshares, a global provider of equity ownership management software and services, today announced the acquisition of Stock & Option Solutions (“SOS” or the “Company”), a U.S.-based specialist in end-to-end equity compensation and plan administration. Stock & Option Solutions brings a track record of supporting the full life cycle of equity and compensation plan administration. Recognized as one of the Inc. 5000 fastest-growing companies in 2022, the Company has built a strong reputation for supporting organizations across the United States, from early-stage startups to large enterprises. Its platform-agnostic service model enables clients to optimize complex incentive structures across major equity technology systems. This acquisition marks a strategic milestone in Allshares’ expansion, establishing the U.S. as Allshares’ largest and fastest-growing market. By integrating SOS’ deep U.S. expertise, Allshares strengthens its ability to deliver seamless ownership management for clients o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom